Predictors of virologic success in patients completing a structured antiretroviral adherence program

Journal of the Association of Nurses in AIDS Care

Volumn 15, Issue 5, 2004, Pages 60-67

  DeFino, Maryrose ^a,b   Clark, Jesse ^a   Mogyoros, Daniel ^a,c   Shuter, Jonathan ^d,e  

^a Qual and Risk Management Department ^*

^b Qual and Risk Management Department

^c Rush Presbyt St Luke's Medican C   (United States)

^d AIDS Center

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adherence; Antiretroviral therapy; Cigarette smoking; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MOTIVATION; PATIENT COMPLIANCE; PREDICTION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

EID: 5444271628     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1177/1055329004269135     Document Type: Article

References (24)

1. Abel, E., & Painter, L. (2003). Factors that influence adherence to HIV medications: Perceptions of women and health care providers. Journal of the Association of Nurses in AIDS Care, 14(4), 61-69.
2. Burkhalter, J., Springer, C., Chhabra, R., et al. (2002, April). Patient-centered health care: Implications for smoking cessation and adherence in a HIV+ Medicaid sample. Paper presented at the 23rd annual meeting of the Society of Behavioral Medicine, Washington, DC.
3. Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hammer, S. M., et al. (2000). Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society USA Panel. Journal of the American Medical Association, 283, 381-390.
4. Chesney, M. A. (2000). Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases, 30(Suppl. 2), S171-176.
5. Davidson, H., Schluger, N. W., Feldman, P. H., Valentine, D. P., Telzak, E. E., & Laufer, F. N. (2000). The effects of increasing incentives on adherence to tuberculosis directly observed therapy. International Journal of Tuberculosis and Lung Disease, 4, 860-865.
6. Deeks, S. G., Hecht, F. M., Swanson, M., Elbeik, T., Loftus, R., Cohen, P. T., et al. (1999). HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS, 13, F35-43.
7. Department of Health and Human Services. (2001, February 25). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: Department of Health and Human Services, Henry J. Kaiser Family Foundation.
8. Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., et al. (2000). Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). Journal of the American Medical Association, 284, 205-211.
9. Diaz, R. M., Ayala, G., Bein, E., Henne, J., & Marin, B. V. (2001). The impact of homophobia, poverty, and racism on the mental health of gay and bisexual Latino men: Findings from 3 US cities. American Journal of Public Health, 91, 927-932.
10. Gulick, R. M., Hu, X. J., Fiscus, S. A., Fletcher, C. V., Haubrich, R., Cheng, H., et al. (2000). Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. Journal of Infectious Diseases, 182, 1375-1384.
11. Haddad, M., Inch, C., Glazier, R. H., Wilkins, A. L., Urbshott, G., Bayoumi, A., et al. (2002). Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. The Cochrane Database of Systematic Reviews, issue 1.
12. Kalichman, S. C., Rompa, D., DiFonzo, K., Simpson, D., Austin, J., Luke, W., et al. (2001). HIV treatment adherence in women living with HIV/AIDS: Research based on the information-motivation-behavioral skills model of health behavior. Journal of the Association of Nurses in AIDS Care, 12(4), 58-67.
13. Kirkland, L. R., Fischl, M. A., Tashima, K. T., Paar, D., Gensler, T., Graham, N. M., et al. (2002). Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed therapy. Clinical Infectious Diseases, 34, 511-518.
14. Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81-87.
15. Lykestos, C., Hoover, D., Guccione, M., Dew, M. A., Wesch, J., Bing, E. G., et al. (1996). Depressive symptoms over the course of HIV infection before AIDS. Social Psychiatry and Psychiatric Epidemiology, 31, 212-219.
16. Maher, K., Klimas, N., Fletcher, M. A., Cohen, V., Maggio, C. M., Triplett, J., et al. (1999). Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs medical center. Journal of Acquired Immune Deficiency Syndromes, 22, 358-363.
17. Mellors, J., Vaida, F., Bennett, K., Hellman, N., DeGruttola, V., & Hammer, S. (2002, February). Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398. Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
18. Niaura, R., Shadel, W. G., Morrow, K., Tashima, K., Flanigan, T., & Abrams, D. B. (2000). Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clinical Infectious Diseases, 31, 808-812.
19. Paredes, R., Mocroft, A., Kirk, O., Lazzarin, A., Barton, S. E., van Lunzen, J., et al. (2000). Predictors of virologic success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA Study. Archives of Internal Medicine, 160, 1123-1132.
20. Pradier, C., Bentz, L., Spire, B., Tourette-Turgis, C., Morin, M., Fuzibet, J. G., et al. (2002, February). Counseling interventions can improve adherence to highly active antiretroviral therapy: Results of a French prospective controlled study. Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
21. Ramirez Garcia, P., & Cote, J. (2003). Factors affecting adherence to antiretroviral therapy in people living with HIV/AIDS. Journal of the Association of Nurses in AIDS Care, 14(4), 37-45.
22. Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., et al. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine, 341, 1865-1873.
23. Tuldra, A., Fumaz, C. R., Ferrer, M. J., Bayes, R., Arno, A., Balague, M., et al. (2000). Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 25, 221-228.
24. Williams, A. (1997). Antiretroviral therapy: Factors associated with adherence. Journal of the Association of Nurses in AIDS Care, 8(Suppl.), 18-23.